Amgen facilities approved
Executive Summary
Two Amgen manufacturing facilities have been approved by FDA, one in West Greenwich, R.I. for production of the inflammation biologic Enbrel (etanercept) and another in Juncos, Puerto Rico, licensed for commercial bulk manufacturing of Neupogen (filgrastim) and Neulasta (pegfilgrastim), the company said. Amgen invested more than $1.1 bil. in the Rhode Island facility, originally licensed in 2002, to expand the campus by 500,000 sq. ft. The company is investing $1.2 bil. to expand the Puerto Rico site, which became operational in 1993. A second facility there will be used for the production of Epogen (epoetin alfa) and Aranesp (darbepoetin alfa)...